REFERENCES
- Dubois R N, Abramson S B, Crofford L, Gupta R A, Simon L S, Putte L BAVD, et al. Cyclooxygenase in biology and disease. FASEB J 1998; 12: 1063–1073
- Kam P CA, See A U-L. Cyclo-oxygenase isoenzymes: physiological and pharmacological role. Anaesthesia 2000; 55: 442–449
- Golden B D, Abramson S B. Selective cyclooxygenase-2 inhibitors. Rheum Dis Clin N Am 1999; 25: 359–378
- Radi Z A, Khan N K. Effects of cyclooxygenase inhibition on the gastrointestinal tract. Exp Toxicol Pathol 2006; 58: 163–173
- Fennerty M B. NSAID-related gastrointestinal injury: evidence-based approach to a preventable complication. Postgrad Med 2001; 110: 163–173
- Whittle B JR. Cyclooxygenase and nitric oxide systems in the gut as therapeutic targets for safer anti-inflammatory drugs. Curr Opin Pharmacol 2004; 4: 538–545
- Whittle B JR. Mechanisms underlying intestinal injury induced by anti-inflammatory COX inhibitors. Eur J Pharmacol 2004; 500: 427–439
- Alsarra I A, Bosela A A, Ahmed S M, Mahrous G M. Proniosomes as a drug carrier for transdermal delivery of ketorolac. Eur J Pharmaceut Biopharmaceut 2005; 59: 485–490
- Mishra A, Veerasamy R, Jain P K, Dixit V K, Agrawal R K. Synthesis, characterization and pharmacological evaluation of amide prodrugs of ketorolac. Eur J Med Chem 2008; 43: 2464–2472
- Puglia C, Filosa R, Peduto A, Caprariis P D, Rizza L, Bonina F, et al. Evaluation of alternative strategies to optimize ketorolac transdermal delivery. AAPS PharmSciTech 2006; 7, Article 64
- Tiwari S B, Udupa N. Investigation into the potential of iontophoresis facilitated delivery of ketorolac. Int J Pharmaceut 2003; 260: 93–103
- Williams A C, Barry B W. Penetration enhancers. Adv Drug Deliv Rev 2004; 56: 603–618
- Gorukanti S R, Li L, Kim K H. Transdermal delivery of antiparkinsonian agent, benztropine. I. Effect of vehicles on skin permeation. Int J Pharmaceut 1999; 192: 159–172
- Liu H, Li S, Wang Y, Yao H, Zhang Y. Effect of vehicles and enhancers on the topical delivery of cyclosporin A. Int J Pharmaceut 2006; 311: 182–186
- Gwak H S, Chun I K. Effect of vehicles and penetration enhancers on the in vitro percutaneous absorption of tenoxicam through hairless mouse skin. Int J Pharmaceut 2002; 236: 57–64
- Panigrahi L, Pattnaik S, Ghosal S K. The effect of pH and organic ester penetration enhancers on skin permeation kinetics of terbutaline sulfate from pseudolatex-type transdermal delivery systems through mouse and human cadaver skins. AAPS PharmSciTech 2005; 6, Article 25
- Mitragotri S. M odeling skin permeability to hydrophilic and hydrophobic solutes based on four permeation pathways. J Controlled Release 2003; 86: 69–92
- Moser K, Kriwet K, Kalia Y N, Guy R H. Enhanced skin permeation of a lipophilic drug using supersaturated formulations. J Controlled Release 2001; 73: 245–253
- El Maghrabya G MM, Campbell M, Finnin B C. Mechanisms of action of novel skin penetration enhancers:Phospholipid versus skin lipid liposomes. International Journal of Pharmaceutics 2005; 305: 90–104
- Refai H, Müller-Goymann C C. The influence of dilution of topical semisolid preparations on hydrocortisone permeation through excised human stratum corneum. European Journal of Pharmaceutics and Biopharmaceutics 2002; 54: 143–150